Cost-effectiveness analysis of combining lenalidomide with R-CHOP for treating diffuse large B-cell lymphoma in China

Cost-effectiveness analysis of combining lenalidomide with R-CHOP for treating diffuse large B-cell lymphoma in China

BackgroundLenalidomide is a thalidomide analog that has immunomodulatory and anti-angiogenic properties. The ECOC-ACRIN E1412 Phase II trial demonstrated that lenalidomide, when combined with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), extended survival in diffuse...

Full description

Saved in:
Bibliographic Details
Main Authors: Rongqi Li, Yuhan Zeng, Yizhang Chen, Zhongjiang Ye, Chuang Chen, Jianhui Yang, Jing Fu, Tao Zhou, Danna Jiang, Sunting Qin, Haige Ye, Ziye Zhou, Xiuhua Zhang
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-12-01
Series:Frontiers in Pharmacology
Subjects:
lenalidomide
R-CHOP
cost-effectiveness
pharmacoeconomic
diffuse large B-cell lymphoma
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2024.1412743/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2024.1412743/full

Similar Items